Imunon Reports Partial Results from Ongoing Non-human Primate Study
October 03, 2022 08:00 ET
|
Imunon, Inc.
Supports PLACCINE Platform as a Viable Alternative to mRNA Vaccines LAWRENCEVILLE, N.J., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Imunon, Inc. (NASDAQ: IMNN), a clinical-stage drug development company,...
Imunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)
September 29, 2022 17:00 ET
|
Imunon, Inc.
LAWRENCEVILLE, N.J., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Imunon, Inc. (NASDAQ: IMNN), a clinical-stage drug development company focused on DNA-based immunotherapy and next-generation vaccines, today...
IMUNON to Present at Chardan’s 6th Annual Genetic Medicines Conference
September 27, 2022 08:30 ET
|
Imunon, Inc.
LAWRENCEVILLE, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Imunon, Inc. (NASDAQ: IMNN), a clinical-stage drug development company, today announced that Dr. Corinne Le Goff, President and Chief...
Celsion Corporation Announces Company Name Change to Imunon, Inc.
September 19, 2022 16:30 ET
|
Celsion Corporation
New name reflects the evolution of the Company’s business focus and its commitment to immunotherapies and vaccines LAWRENCEVILLE, N.J., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Celsion...
Celsion Completes Enrollment of the Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer
September 15, 2022 08:30 ET
|
Celsion Corporation
110 Patients Enrolled in Study Comparing Novel Gene-Mediated Immunotherapy plus Neoadjuvant Chemotherapy versus Neoadjuvant Chemotherapy Alone LAWRENCEVILLE, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE)...
Celsion Corporation Presentation Time at the H.C. Wainwright 24th Annual Global Investment Conference Changed to 4:30 p.m. ET on September 13
September 12, 2022 18:30 ET
|
Celsion Corporation
LAWRENCEVILLE, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company, announces that Dr. Corinne Le Goff, President and Chief...
Celsion Corporation to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 07, 2022 09:15 ET
|
Celsion Corporation
LAWRENCEVILLE, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company today announced that Dr. Corinne Le Goff, President and Chief...
Celsion Corporation Highlights Progress in its DNA-based Vaccine Program
September 01, 2022 08:30 ET
|
Celsion Corporation
PLACCINE DNA-based Vaccine Demonstrates Robust Response in Murine Model LAWRENCEVILLE, N.J., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company...
Celsion Corporation Reports Second Quarter 2022 Financial Results and Provides Business Update
August 15, 2022 08:00 ET
|
Celsion Corporation
DNA Mediated Immunotherapy and Next-Generation Vaccine Programs Supported with a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. EDT LAWRENCEVILLE, N.J., Aug. ...
Celsion Corporation to Hold Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 15, 2022
August 08, 2022 08:30 ET
|
Celsion Corporation
LAWRENCEVILLE, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines,...